GTx, Inc. Presents at Lazard Capital Markets Conference

GTx, Inc., the Men's Health Biotech Company, announced its participation in the Lazard Capital Markets Third Annual Life Sciences Conference. The company presented a company overview on November 29 at the New York Palace Hotel. The presentation was webcast and remains available on the GTx website. This event highlights GTx's ongoing efforts in developing therapeutics for cancer and men's health.

Key Takeaways:

• GTx is a biopharmaceutical company with a focus on developing small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones.
• The company is developing ACAPODENE (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs: one for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and another for the prevention of prostate cancer in high-risk men with high-grade PIN.
• GTx has licensed ACAPODENE to Ipsen Group for development and commercialization in Europe for the prevention of prostate cancer and treatment of multiple side effects of androgen deprivation therapy.
• Ostarine, a selective androgen receptor modulator, or SARM, is being evaluated in a Phase II clinical trial for muscle wasting and bone loss indications in 120 elderly men and postmenopausal women.
• GTx has licensed another SARM, andarine, to Ortho Biotech Products, L.P., under a joint collaboration and license agreement.
• Forward-looking statements in the press release indicate potential risks and uncertainties associated with GTx's product development and commercialization efforts.
• The company's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 3, 2006, provides a comprehensive description of these risks and uncertainties.

Statistics:

• The Phase I clinical trial for ACAPODENE is ongoing (no specific enrollment date mentioned).
• The Phase II clinical trial for ostarine is ongoing and expects to have data in the fourth quarter of 2006 (specific enrollment date not mentioned).
• GTx has a significant portfolio of small molecules under development, including ACAPODENE and ostarine.
• The company has licensed its SARMs, ostarine and andarine, to Ipsen Group and Ortho Biotech Products, L.P., respectively, for development and commercialization.

Sources:

• GTx, Inc., Press Release, November 29 (no specific year mentioned)
• GTx, Inc., Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission, November 3, 2006